There’s GVDs, and there’s redthread GVDs.
Two things make a redthread GVD different. Brief and execution.
The brief is critical. It tells us what type of GVD you need. GVDs are not made equal, and a GVD for reimbursement will differ from a dossier built for early messaging and strategy.
And when it comes to execution, we focus on telling a story, supported by robust data. Not an easy task for a large, complex document, but that’s where we add real value.
Too often the story gets lost in a GVD.
We founded redthread to put the story back.
Core Deliverables
- Global value dossiers
- Payer value propositions
- Objection handling
- In-field market access tactics
- Publications and congress support
- Global value dossiers
- Payer value propositions
- Objection handling
- In-field market access tactics
- Publications and congress support
Let us tell your story
We can also bring our story-telling expertise to your value proposition.
Mark Twain once said “I apologize for such a long letter – I didn’t have time to write a short one”. He wasn’t talking about value propositions, but he should have been. Writing a long one is relatively easy, but a brilliant one takes real expertise.
Starting always from the foundation of therapy area immersion – and incorporating primary research to validate messaging where required – our development process stress-tests messaging, and objections, with key stakeholders before approval.
Beyond GVDs and PVPs
Objection handling often goes hand-in-hand with value proposition development, and we can help identify key payer questions across global markets and plan mitigating responses.
We can also support your publications planning and execution, though we typically restrict this to HEOR, PRO, and RWE publications, posters and oral presentations. And you’ll get most value from us if you’re trying to communicate a tricky market access or HEOR topic visually and succinctly, whether to an internal or external audience.
Related Case Studies
Cross-company collaboration on a NICE HTA
Seamless collaboration with Delta Hat to deliver NICE & SMC submissions under tight timelines…
HTA scientific advice for a cell therapy in lymphoma
Supporting Global and UK pharma with early dialogue in the UK and France…
Read more from HTA scientific advice for a cell therapy in lymphoma